United-Guardian Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Form 10-Q) | 6 Nov 2026 |
| FY 2026 Annual Earnings Release (Form 10-K) | 12 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Renacidin Sales Growth Quarterly2,400.0%Target: Maintain double-digit growth through expanded healthcare practitioner (HCP) awareness campaigns
Cosmetic Ingredient Sales Growth Quarterly2,100.0%Target: Stabilize and grow via normalized distributor purchasing patterns and new product launches
Ashland Specialty Ingredients (ASI) Purchase Growth Quarterly4,500.0%Target: Sustain normalized inventory levels and consistent reordering patterns
Watch Items
- Medicare Part D Rebate LiabilitiesTrigger: Phase-in period progression toward 2031Action: Monitor financial impact of the Inflation Reduction Act's manufacturer discount program on Renacidin margins
- Cosmetic Ingredient Competition in AsiaTrigger: Market share erosion or pricing pressure from local Chinese producersAction: Accelerate R&D of natural/environmentally friendly specialty ingredients and expand international distribution agreements
- Natrajel Commercialization in Sexual Wellness SegmentTrigger: Receipt of subsequent commercial-scale orders from distributor BrenntagAction: Support distributor marketing efforts and track customer regulatory navigation
Research as of 20 Jun 2026